Study: Neupro Transdermal System Shows Therapeutic Benefit in RLS

UCB on Wednesday announced the results of a six-month, randomized, double-blind, placebo-controlled clinical study … showing that Neupro (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of restless legs syndrome (RLS).
Forbes